Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Morote

Showing results (1-10 of 196) with videos related to

Pageof 20
Sort By:
BJU International|May 28, 2026
Response to the Letter by Carey and Kommu: 'Generating a consensus on the follow-up of multifocal high-grade prostate intraepithelial neoplasia'Juan Morote
European Urology Oncology|March 9, 2023
Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126-37Juan Morote
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 2022
The importance of appropriate castrate level measurements of serum testosterone in prostate cancer patientsJuan Morote
European Urology|October 27, 2009
Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-68Juan Morote
Actas Urologicas Espanolas|August 29, 2009
[Impact of prostate cancer screening on mortality]Juan Morote Robles
Medicina Clinica|June 8, 2006
[Is the era of prostatic specific antigen over?]Juan Morote-Robles
Archivos Espanoles De Urologia|February 8, 2007
[Prostatic cancer. New diagnostic techniques]Juan Morote Robles
Medicina Clinica|March 12, 2004
[Measurement of complexed prostatic specific antigen. A new challenge in PSA era]Juan Morote Robles
The Journal of Urology|October 7, 2020
Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate CancerJuan Morote, Imma Comas
European Urology|October 4, 2011
Antihypertensive drugs and the risk of prostate cancerJuan Morote, Jacques Planas
Pageof 20

Showing results (1-10 of 196) with videos related to

Sort By:
Pageof 20
BJU International|May 28, 2026
Response to the Letter by Carey and Kommu: 'Generating a consensus on the follow-up of multifocal high-grade prostate intraepithelial neoplasia'Juan Morote
European Urology Oncology|March 9, 2023
Re: Jonas Hugosson, Marianne Månsson, Jona Wallström, et al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med 2022;387:2126-37Juan Morote
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 2022
The importance of appropriate castrate level measurements of serum testosterone in prostate cancer patientsJuan Morote
European Urology|October 27, 2009
Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-68Juan Morote
Actas Urologicas Espanolas|August 29, 2009
[Impact of prostate cancer screening on mortality]Juan Morote Robles
Medicina Clinica|June 8, 2006
[Is the era of prostatic specific antigen over?]Juan Morote-Robles
Archivos Espanoles De Urologia|February 8, 2007
[Prostatic cancer. New diagnostic techniques]Juan Morote Robles
Medicina Clinica|March 12, 2004
[Measurement of complexed prostatic specific antigen. A new challenge in PSA era]Juan Morote Robles
The Journal of Urology|October 7, 2020
Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate CancerJuan Morote, Imma Comas
European Urology|October 4, 2011
Antihypertensive drugs and the risk of prostate cancerJuan Morote, Jacques Planas
Pageof 20